Search

CN-121987657-A - MiRNA miR-148b-3p for targeted regulation of SLC7A11 action in breast cancer and action mechanism and application thereof

CN121987657ACN 121987657 ACN121987657 ACN 121987657ACN-121987657-A

Abstract

The invention provides miRNA miR-148b-3p for targeted regulation of the action of SLC7A11 in breast cancer, and an action mechanism and application thereof, and the miRNA miR-148b-3p can inhibit proliferation and migration of breast cancer cells through targeted regulation of SLC7A 11. Related action mechanisms are revealed through researches such as ceRNA network construction, and potential targets and strategies are provided for breast cancer treatment. Meanwhile, the compound has a regulating and controlling effect in other cancers but has weaker effect than that of breast cancer, the specific regulating and controlling effect on the breast cancer is highlighted, and a solid theoretical basis is laid for the accurate treatment of the breast cancer, so that the treatment and research of the breast cancer are more effectively carried out.

Inventors

  • ZHANG LEI
  • MA GUANNAN
  • NIU KAIFENG
  • QIN LAN

Assignees

  • 杭州迪安医学检验中心有限公司

Dates

Publication Date
20260508
Application Date
20241105

Claims (10)

  1. 1. The application of miRNA in preparing a preparation for regulating proliferation activity or migration capacity of tumor cells is characterized in that the miRNA is miR-148b-3p, and the nucleotide sequence of the miR-148b-3p is shown as SEQ ID NO.1 and SEQ ID NO. 2.
  2. 2. The use according to claim 1, wherein the gene related to proliferation activity or migration ability of the tumor cell is SLC7A11 gene, and the expression of SLC7A11 gene can be regulated by regulating the expression level of miR-148b-3p, so that proliferation activity or migration ability of the tumor cell can be regulated.
  3. 3. The use of claim 2, wherein the proliferation activity and migration capacity of the tumor cell is reduced or increased by up-regulating or down-regulating the amount of miR-148b-3p expression and inhibiting or promoting the expression of the SLC7a11 gene.
  4. 4. The use of claim 3, wherein the expression of the SLC7A11 gene is inhibited by adding a miR-148b-3p analogue, the proliferation activity and migration capacity of tumor cells are inhibited, and the expression of the SLC7A11 gene is improved by adding a miR-148b-3p inhibitor, and the proliferation activity and migration capacity of tumor cells are improved.
  5. 5. The use of claim 4, wherein the miR-148b-3p inhibitor has a nucleotide sequence set forth in seq id No. 3.
  6. 6. The use of claim 5, wherein the miR-148b-3p analog or miR-148b-3p inhibitor is added to the tumor cell via a transfection reagent.
  7. 7. The use of claim 6, wherein the tumor cells comprise any one or a combination of breast cancer cells, colon cancer cells, or liver cancer cells.
  8. 8. The use of claim 7, wherein the tumor cells comprise breast cancer cells.
  9. The application of the miR-148b-3p inhibitor in preparing a preparation for regulating proliferation activity or migration capacity of tumor cells is characterized in that the nucleotide sequence of the miR-148b-3p inhibitor is shown as SEQ ID NO. 3.
  10. 10. The use of claim 9, wherein increasing expression of the SLC7A11 gene by adding a miR-148b-3p inhibitor increases proliferation activity and migration capacity of tumor cells, including any one or a combination of breast cancer cells, colon cancer cells or liver cancer cells.

Description

MiRNA miR-148b-3p for targeted regulation of SLC7A11 action in breast cancer and action mechanism and application thereof Technical Field The invention relates to the technical field of biology, in particular to miRNA miR-148b-3p for targeted regulation of SLC7A11 action in breast cancer, and an action mechanism and application thereof. Background Cancer is one of the diseases that severely threatens human health worldwide, and its occurrence and development involves a variety of complex molecular mechanisms. In recent years, it has been found that solute carrier family 7 member 11 (SLC 7a 11) plays an important role in cancer. SLC7a11 is a multipass transmembrane protein that mediates extracellular cystine uptake and exchange glutamate, playing a vital role in cell growth, proliferation and metabolism. As a key cellular mechanism against iron death, the SLC7a11-GSH system affects intracellular cystine and glutathione levels by regulating cystine metabolic pathways, thereby affecting cell death. Currently, more and more studies indicate that SLC7a11 is overexpressed in a variety of tumors, the expression levels of which are closely related to tumor cell proliferation, invasion, metastasis and tumor microenvironment. For example, in lung cancer, has-mir-373 and Has-mir-372 can up-regulate SLC7A11 expression by competitive binding, regulate immune infiltration in lung adenocarcinoma, in melanoma SLC7A11 increases intracellular GSH levels, confers resistance to BRAF inhibitors, and in bladder cancer, inhibition of SLC7A11 expression can reverse resistance of resistant cells to cisplatin. However, there is little systematic study on SLC7a11 in pan-carcinoma, and the underlying molecular mechanisms of its level changes during cancer formation are not yet fully understood. In breast cancer, the expression of SLC7A11 is positively correlated with tumor immune cell infiltration, and high expression is obviously correlated with poor prognosis, which suggests that the SLC7A11 can be used as a biomarker for the poor prognosis of breast cancer patients. However, it is not clear how cancer, particularly breast cancer, can be inhibited by SLC7A 11. Microribonucleic acid (miRNA) is an endogenous non-coding single-stranded RNA molecule, and can be combined with a 3' -untranslated region of a target gene to negatively regulate the expression and cell functions of the target gene. Studies have shown that miR-148a-3p promotes malignant behavior of breast cancer cells by downregulating DUSP1, but miRNA or mechanism for targeted regulation of SLC7A11 gene to inhibit breast cancer is not clear. Therefore, in order to deeply understand the action mechanism of SLC7A11 in cancers, an effective method for inhibiting cancers, especially breast cancers, is sought, and an action mechanism of SLC7A11 for inhibiting cancers and a novel miRNA capable of targeted regulation of SLC7A11 are needed, so that the aim of inhibiting breast cancers is fulfilled by regulating and controlling the expression level of miRNA in vivo and further targeted regulation of SLC7A11 genes. Disclosure of Invention In order to solve the problems in the prior art, the invention provides miRNA miR-148b-3p for targeted regulation and control of the action of SLC7A11 in breast cancer and an action mechanism and application thereof, a ceRNA network is constructed to predict and screen miR-148b-3p, the miR-148b-3p can be found and proved for the first time to inhibit proliferation and migration of breast cancer cells through targeted regulation and control of SLC7A11, meanwhile, the change of related indexes after transfection of a miR-148b-3p inhibitor is verified through a cell experiment, the effect mechanism of SLC7A11 in breast cancer is disclosed to be related to the regulation and control of miR-148b-3p, a new view angle is provided for deep understanding of the mechanism of occurrence and development of breast cancer, a potential target point and strategy of breast cancer treatment are provided, the regulation and control effect and specificity of miR-148b-3p in other cancers are found, the regulation and control effect on the other cancers is relatively weak, the relatively specific regulation and control effect on breast cancer is highlighted, and a solid theory is provided for accurate treatment of breast cancer. In order to achieve the above purpose, the invention is realized by adopting the following scheme: In one aspect, the invention provides an application of miRNA (micro ribonucleic acid) in preparing a preparation for regulating proliferation activity or migration capacity of tumor cells, wherein the miRNA is miR-148b-3p, and the nucleotide sequence of miR-148b-3p is shown as SEQ ID NO.1 and SEQ ID NO. 2. In order to understand the action mechanism of SLC7A11 in cancer deeply, an effective method for inhibiting cancer, especially breast cancer is sought, in the invention, systematic pan-cancer analysis of SLC7A11 and targeted research on breast canc